search
Back to results

Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in Acute Pancreatitis (WATERFALL)

Primary Purpose

Acute Pancreatitis

Status
Terminated
Phase
Phase 3
Locations
Spain
Study Type
Interventional
Intervention
Lactated Ringer Solution
Sponsored by
Enrique de-Madaria
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Pancreatitis focused on measuring Acute pancreatitis; fluid resuscitation; therapy; outcomes; randomized controlled trial; Ringer lactate; Lactated Ringer's solution

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients age greater or equal to 18 presenting to one of the collaborating centers
  • Diagnosis of acute pancreatitis according to the revised Atlanta classification which requires 2 of the following 3 criteria: A) Typical abdominal pain; B) Increase in serum amylase or lipase levels higher than 3 times the upper limit of normality; and C) Signs of AP in imaging.

Exclusion Criteria:

  • Uncontrolled arterial hypertension (systolic blood pressure >180 and/or diastolic blood pressure 100 mmHg);
  • New York Heart Association Class II hear failure (slight limitation of physical activity; fatigue, palpitations or dyspnea with ordinal physical activity) or worse, or ejection fraction<50% in the last echocardiography;
  • Decompensated cirrhosis (Child's Class B or C);
  • Hyper or hyponatremia (<135 or >145 mEq/l);
  • Hyperkalemia (>5 mEq/l);
  • Hypercalcemia (albumin or protein-corrected calcium>10.5 mg/dl);
  • Chronic kidney failure (basal glomerular filtration rate <60 mL/min/1.73m2);
  • Clinical signs or symptoms of volume overload or heart failure at recruitment (dyspnea, peripheral edema, pulmonary rales, or evident increased jugular ingurgitation at 45º);
  • Shock or respiratory failure according to the revised Atlanta classification at recruitment (non-fluid responding systolic blood pressure< 90 mmHg, PaO2/FIO2≤300 mmHg);
  • Time from pain onset to arrival to emergency room >24h;
  • Time from confirmation of pancreatitis to randomization >8h;
  • Severe comorbidity associated with an estimated life expectancy <1 year;
  • Confirmed chronic pancreatitis (in case of recurrent alcoholic pancreatitis a recent (<6 months) CT scan/MRI or endoscopic ultrasound is needed to rule out chronic pancreatitis

Sites / Locations

  • Alicante
  • Hospital General Universitario de Alicante

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Aggressive fluid resuscitation

Moderate fluid resuscitation

Arm Description

Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h. At 12(±4) hours: A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours

At recruitment: A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h. B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus). At 12(±4) hours: A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours

Outcomes

Primary Outcome Measures

Moderate-to-severe acute pancreatitis
Moderate or severe category of the Revised Atlanta Classification (Banks et al, Gut 2013)

Secondary Outcome Measures

Death and/or persistent organ failure and/or infection of pancreatic necrosis
Analyzed as a composite endpoint and each of its components, includes in-hospital mortality, persistent organ failure (according to the revised Atlanta classification, Banks et al, Gut 2013) or infection of pancreatic necrosis
Fluid overload
Fluid overload is defined by the absence of Acute Respiratory Distress Syndrome and at least 2 of the following 3 criteria (based on Sharma et al, Lancet Diabetes Endocrinol 2016, with modifications): Criteria 1. Hemodynamic-imaging evidence (≥1): Non-invasive diagnostic evidence of heart failure (i.e., echocardiographic, cardiac MRI) Radiographic evidence of pulmonary congestion Invasive cardiac catheterization suggesting evidence of heart failure (i.e., pulmonary capillary wedge pressure [or left ventricular end-diastolic pressure] >18 mm Hg, right arterial pressure [or central venous pressure] >12 mm Hg, or cardiac index < 2·2 L/min per m2) Criteria 2. Heart failure symptoms (1): - Dyspnea Criteria 3. Heart failure signs (≥1): Peripheral edema Pulmonary rales or crackles, or crepitation Increased jugular venous pressure, hepatojugular reflux, or both
Shock
Systolic blood pressure <90 mmHg after fluid resuscitation
Respiratory failure
PaO2/FIO2<300
Kidney failure
Creatinine >1.9 mg/dL
Local complications (acute peripancreatic fluid collections/ pancreatic necrosis/peripancreatic necrosis)
As described on the revised Atlanta classification, Banks et al, Gut 2013
Length of hospital stay
Intensive care unit stay
Need for intensive care unit (ICU) admission, and days admitted in the ICU
Need for invasive treatment
Endoscopic, percutaneous or surgical treatment of acute pancreatitis complications
Need for nutritional support
Need for enteral/parenteral feeding
PAN-PROMISE scale
Score on an acute pancreatitis Patient-Reported Outcome Measurement
C-reactive protein
Blood levels of C-reactive protein
Systemic inflammatory response syndrome (SIRS)
SIRS at the different checkpoints. Presence of persistent (>48h) SIRS

Full Information

First Posted
May 2, 2020
Last Updated
March 4, 2022
Sponsor
Enrique de-Madaria
Collaborators
Instituto de Salud Carlos III, Asociación Española de Gastroenterología, Asociación Española de Pancreatología
search

1. Study Identification

Unique Protocol Identification Number
NCT04381169
Brief Title
Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in Acute Pancreatitis
Acronym
WATERFALL
Official Title
Effect of Early Weight-based Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in the Early Phase of Acute Pancreatitis: an Open-label Multicenter Randomized-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Terminated
Why Stopped
Increased frequency of fluid overload on the aggressive fluid resuscitation arm of treatment
Study Start Date
May 28, 2020 (Actual)
Primary Completion Date
September 25, 2021 (Actual)
Study Completion Date
September 25, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Enrique de-Madaria
Collaborators
Instituto de Salud Carlos III, Asociación Española de Gastroenterología, Asociación Española de Pancreatología

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
WATERFALL is an investigator-initiated international multicenter open-label randomized clinical trial comparing aggressive versus moderate fluid resuscitation in acute pancreatitis. The main outcome variable will be the proportion of patients with moderate-to-severe AP. Aggressive fluid resuscitation will consist in Lactated Ringer Solution (LR) 20 ml/kg bolus (administered over 2 hours) followed by LR 3 ml/kg/h and moderate a LR bolus 10 ml/kg in case of hypovolemia or no bolus in patients with normal volemia, followed by LR 1.5 ml/kg/h. The patients will be assessed at 3 (±1), 12 (±4), 24 (±4), 48 (±4) and 72 (±4) hours from recruitment, and fluid resuscitation will be adjusted to the patient´s clinical and analytical status according to a protocol. Subgroup analysis will include patients with systemic inflammatory response syndrome (SIRS) at admission, with persistent (>48h) SIRS and with hypovolemia at admission. Based on available data (Sternby et al, Ann Surg 2019) we expect a 35% incidence of moderate to severe AP in the moderate arm. Sample sizes of 372 per arm of treatment (744 patients) achieve 80% power to detect a difference of 10% between the treatment arms at a significance level (alpha) of 0.05 using a two-sided z-testNA, assuming a 10% dropout. These results assume that 3 sequential tests are made using the O'Brien-Fleming spending function to determine the test boundaries. All analyses will be performed on an intention-to-treat basis. The trial could be stop early for efficacy (primary end-point) if the observed two-sided P value is <0.0002 at the first interim analysis (after 1/3 of patients have been enrolled) or is <0.012 at second interim analysis (after 2/3 of patients have been enrolled), favoring aggressive fluid resuscitation. At final analysis, the hypothesis that the incidence of moderate-to-severe pancreatitis is similar in the two treatment arms will be rejected if p<0.046

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pancreatitis
Keywords
Acute pancreatitis; fluid resuscitation; therapy; outcomes; randomized controlled trial; Ringer lactate; Lactated Ringer's solution

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
249 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aggressive fluid resuscitation
Arm Type
Experimental
Arm Description
Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h. At 12(±4) hours: A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours
Arm Title
Moderate fluid resuscitation
Arm Type
Experimental
Arm Description
At recruitment: A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h. B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus). At 12(±4) hours: A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours
Intervention Type
Drug
Intervention Name(s)
Lactated Ringer Solution
Other Intervention Name(s)
Aggressive fluid resuscitation, Moderate fluid resuscitation, Restrictive fluid resuscitation
Intervention Description
Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
Primary Outcome Measure Information:
Title
Moderate-to-severe acute pancreatitis
Description
Moderate or severe category of the Revised Atlanta Classification (Banks et al, Gut 2013)
Time Frame
From admission to discharge, up to 24 weeks
Secondary Outcome Measure Information:
Title
Death and/or persistent organ failure and/or infection of pancreatic necrosis
Description
Analyzed as a composite endpoint and each of its components, includes in-hospital mortality, persistent organ failure (according to the revised Atlanta classification, Banks et al, Gut 2013) or infection of pancreatic necrosis
Time Frame
From admission to discharge, up to 24 weeks
Title
Fluid overload
Description
Fluid overload is defined by the absence of Acute Respiratory Distress Syndrome and at least 2 of the following 3 criteria (based on Sharma et al, Lancet Diabetes Endocrinol 2016, with modifications): Criteria 1. Hemodynamic-imaging evidence (≥1): Non-invasive diagnostic evidence of heart failure (i.e., echocardiographic, cardiac MRI) Radiographic evidence of pulmonary congestion Invasive cardiac catheterization suggesting evidence of heart failure (i.e., pulmonary capillary wedge pressure [or left ventricular end-diastolic pressure] >18 mm Hg, right arterial pressure [or central venous pressure] >12 mm Hg, or cardiac index < 2·2 L/min per m2) Criteria 2. Heart failure symptoms (1): - Dyspnea Criteria 3. Heart failure signs (≥1): Peripheral edema Pulmonary rales or crackles, or crepitation Increased jugular venous pressure, hepatojugular reflux, or both
Time Frame
From admission to discharge, up to 24 weeks
Title
Shock
Description
Systolic blood pressure <90 mmHg after fluid resuscitation
Time Frame
From admission to discharge, up to 24 weeks
Title
Respiratory failure
Description
PaO2/FIO2<300
Time Frame
From admission to discharge, up to 24 weeks
Title
Kidney failure
Description
Creatinine >1.9 mg/dL
Time Frame
From admission to discharge, up to 24 weeks
Title
Local complications (acute peripancreatic fluid collections/ pancreatic necrosis/peripancreatic necrosis)
Description
As described on the revised Atlanta classification, Banks et al, Gut 2013
Time Frame
From admission to discharge, up to 24 weeks
Title
Length of hospital stay
Time Frame
From admission to discharge, up to 24 weeks
Title
Intensive care unit stay
Description
Need for intensive care unit (ICU) admission, and days admitted in the ICU
Time Frame
From admission to discharge, up to 24 weeks
Title
Need for invasive treatment
Description
Endoscopic, percutaneous or surgical treatment of acute pancreatitis complications
Time Frame
From admission to discharge, up to 24 weeks
Title
Need for nutritional support
Description
Need for enteral/parenteral feeding
Time Frame
From admission to discharge, up to 24 weeks
Title
PAN-PROMISE scale
Description
Score on an acute pancreatitis Patient-Reported Outcome Measurement
Time Frame
At 12, 24, 48 and 72 hours
Title
C-reactive protein
Description
Blood levels of C-reactive protein
Time Frame
48 and 72 hours
Title
Systemic inflammatory response syndrome (SIRS)
Description
SIRS at the different checkpoints. Presence of persistent (>48h) SIRS
Time Frame
Baseline, 12, 24, 48 and 72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients age greater or equal to 18 presenting to one of the collaborating centers Diagnosis of acute pancreatitis according to the revised Atlanta classification which requires 2 of the following 3 criteria: A) Typical abdominal pain; B) Increase in serum amylase or lipase levels higher than 3 times the upper limit of normality; and C) Signs of AP in imaging. Exclusion Criteria: Uncontrolled arterial hypertension (systolic blood pressure >180 and/or diastolic blood pressure 100 mmHg); New York Heart Association Class II hear failure (slight limitation of physical activity; fatigue, palpitations or dyspnea with ordinal physical activity) or worse, or ejection fraction<50% in the last echocardiography; Decompensated cirrhosis (Child's Class B or C); Hyper or hyponatremia (<135 or >145 mEq/l); Hyperkalemia (>5 mEq/l); Hypercalcemia (albumin or protein-corrected calcium>10.5 mg/dl); Chronic kidney failure (basal glomerular filtration rate <60 mL/min/1.73m2); Clinical signs or symptoms of volume overload or heart failure at recruitment (dyspnea, peripheral edema, pulmonary rales, or evident increased jugular ingurgitation at 45º); Shock or respiratory failure according to the revised Atlanta classification at recruitment (non-fluid responding systolic blood pressure< 90 mmHg, PaO2/FIO2≤300 mmHg); Time from pain onset to arrival to emergency room >24h; Time from confirmation of pancreatitis to randomization >8h; Severe comorbidity associated with an estimated life expectancy <1 year; Confirmed chronic pancreatitis (in case of recurrent alcoholic pancreatitis a recent (<6 months) CT scan/MRI or endoscopic ultrasound is needed to rule out chronic pancreatitis
Facility Information:
Facility Name
Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Facility Name
Hospital General Universitario de Alicante
City
Alicante
ZIP/Postal Code
03550
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23100216
Citation
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.
Results Reference
background
PubMed Identifier
36103415
Citation
de-Madaria E, Buxbaum JL, Maisonneuve P, Garcia Garcia de Paredes A, Zapater P, Guilabert L, Vaillo-Rocamora A, Rodriguez-Gandia MA, Donate-Ortega J, Lozada-Hernandez EE, Collazo Moreno AJR, Lira-Aguilar A, Llovet LP, Mehta R, Tandel R, Navarro P, Sanchez-Pardo AM, Sanchez-Marin C, Cobreros M, Fernandez-Cabrera I, Casals-Seoane F, Casas Deza D, Lauret-Brana E, Marti-Marques E, Camacho-Montano LM, Ubieto V, Ganuza M, Bolado F; ERICA Consortium. Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis. N Engl J Med. 2022 Sep 15;387(11):989-1000. doi: 10.1056/NEJMoa2202884.
Results Reference
derived

Learn more about this trial

Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in Acute Pancreatitis

We'll reach out to this number within 24 hrs